Parkinson's Disease Mechanisms encompasses the diverse molecular and cellular processes that underlie Parkinson's disease (PD), the second most common neurodegenerative disorder. This page provides a comprehensive overview of the clinical features, neuropathology, molecular mechanisms, genetic factors, and therapeutic approaches for PD.
Parkinson's disease is a progressive neurodegenerative disorder affecting millions of people worldwide. The disease is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies. Understanding the underlying mechanisms is crucial for developing disease-modifying therapies.
Parkinson's disease (PD) is the second most common neurodegenerative, characterized by progressive loss of dopaminergic disorder after Alzheimer's disease neurons in the substantia nigra pars compacta and the presence of Lewy bodies.
The study of Parkinson'S Disease Mechanisms has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. PMID:25904081
Poewe W, et al. Parkinson's disease. Nat Rev Dis Primers. 2017;3:17013. PMID:28332488
Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839-840. PMID:9278044
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015;85(2):257-273. PMID:25611507
Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211. PMID:12498954
Surmeier DJ, et al. Alpha-synuclein and Lewy body-like pathology in models of Parkinson disease. Nat Med. 2018;24(8):1192-1204. PMID:29967348
Dexter DT, et al. Basal lipids in substantia nigra in Parkinson's disease. J Neurochem. 1989;53(5):1423-1427. PMID:2677201
Lang AE, Lozano AM. Parkinson's disease. N Engl J Med. 1998;339(15):1044-1053. PMID:9761806
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 8 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 29%